Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ PODN Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA599862
Description
Antibody detects endogenous levels of total PODN.
Non-collagenous proteins of the small leucine-rich repeat (SLR) protein family are considered important components of the extracellular matrix. The extracellular matrix plays an integral role in the pivotal processes of development, tissue repair and metastasis by regulating cell proliferation, differentiation, adhesion and migration. Podocan, also known as PCAN, SLRR5A or PODN, is a 613 amino acid secreted protein belonging to the small leucine-rich proteoglycan (SLRP) family and the class V subfamily. Expressed in kidney, heart, liver, pancreas and vascular smooth muscle cells, Podocan exists as three alternatively spliced isoforms containing twenty LRR (leucine-rich repeats), a unique N-terminal cysteine-rich cluster pattern and a highly acidic C-terminal domain. Podocan is considered a glycoprotein containing N-linked oligosaccharides that may be involved in growth regulation in cardiovascular tissues. Encoded by a gene located on human chromosome 1, Podocan interacts type I collagen (COL1).
Specifications
PODN | |
Polyclonal | |
Unconjugated | |
Podn | |
9430070G18; Pcan; Podn; Podocan; podocan proteoglycan; PRO332; SLRR5A; UNQ293; UNQ293/PRO332 | |
Rabbit | |
Affinity chromatography | |
RUO | |
127435 | |
-20°C | |
Liquid |
Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q7Z5L7 | |
Podn | |
A synthesized peptide derived from human PODN(Accession Q7Z5L7), corresponding to amino acid residues V66-L116. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction